Zhangzhou Pientzehuang Pharmaceutical (600436) H2 2025 earnings summary

Executive summary

• Revenue for 2025 was RMB 9.00 billion, down 16.56% year-over-year; net profit attributable to shareholders was RMB 2.16 billion, down 27.49% year-over-year.

• Gross margin declined to 36.49%, a decrease of 6.35 percentage points from the previous year.

• Cash flow from operating activities dropped sharply by 94.14% year-over-year to RMB 77 million.

• The company maintained a strong balance sheet with total assets of RMB 17.56 billion and net assets attributable to shareholders of RMB 14.54 billion.

• Proposed cash dividend of RMB 15.70 per 10 shares, with total cash dividends for the year reaching RMB 1.79 billion, representing 83.01% of net profit.

Financial highlights

• Operating income: RMB 9.00 billion, down 16.56% year-over-year.

• Net profit attributable to shareholders: RMB 2.16 billion, down 27.49% year-over-year.

• Basic EPS: RMB 3.58, down 27.38% year-over-year.

• Gross margin: 36.49%, down 6.35 percentage points year-over-year.

• Cash flow from operations: RMB 77 million, down 94.14% year-over-year.

Outlook and guidance

• Focus on strengthening core brand and product matrix, expanding domestic and international markets, and accelerating R&D and digital transformation.

• Plans to launch new clinical trials and product registrations, and to deepen integration of traditional Chinese medicine with innovative therapies.

• Continued emphasis on cost control, risk management, and quality assurance amid tightening regulatory environment.